Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
AMADEUS TRIAL: TUMOR AGNOSTIC PRE- AND ONTREATMENT BIOMARKERS OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB CORRELATE WITH ONTREATMENT TUMORAL T CELL INFILTRATION
À¶Ý®ÊÓƵ
AMADEUS TRIAL: TUMOR AGNOSTIC PRE- AND ONTREATMENT BIOMARKERS OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB CORRELATE WITH ONTREATMENT TUMORAL T CELL INFILTRATION Alayli, F., Okrah, K., Tsimberidou, A., Drakaki, A., Khalil, D., Khan, S., Hodi, S., Oh, D., Amouzgar, M., Guatam, S., Kageyama, R., Pfeiffer, S., Meier, S., Cabanski, C., Da Silva, D., Kumar, D., Santulli-Marotto, S., Tetzlaff, M., Foo, W., Hollman, T., Li, Y., Adamow, M., Wong, P., Spasic, M., Chen, R., Bucktrout, S., Fairchild, J., Butterfield, L., LaVallee, T., Padron, L., Salvador, L., O'Donnell-Tormey, J., Dugan, U., Sharma, P. BMJ PUBLISHING GROUP. 2022: A614View details for
View details for